The Uneven Pace of Innovation: Why US Pharma Execs Lag Behind China in Embracing AI The latest survey on the adoption of artificial intelligence (AI) in pharmaceutical research and development reveals a stark contrast between two nations' approaches to innovation.
While China is rapidly integrating AI into its pharma industry, only 24% of US pharma executives believe it holds significant potential.
This disparity raises important questions about the pace and willingness to adapt to emerging technologies in the American pharmaceutical sector.